Your best medicine news resource
May 15th 2008Drug InformationCystic Fibrosis
The Alabama Department of Public Health in partnership with the cystic fibrosis centers at the University of Alabama at Birmingham, Children’s Hospital of Alabama and the University of South Alabama announces further significant expansion of Alabama’s newborn screening program. On April 21, Alabama will add cystic fibrosis to its panel of primary newborn screening tests.
More: continued here
May 15th 2008Drug InformationCystic Fibrosis
Scientists from the UK CF Gene Therapy Consortium funded by the Cystic Fibrosis Trust have overcome a major obstacle in their ground-breaking gene therapy programme for Cystic Fibrosis. Cystic Fibrosis (CF) is the UK’s most common life-threatening inherited disease and is caused by a single defective gene.
More: continued here
May 15th 2008Drug InformationCystic Fibrosis
Alabama has joined 39 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. “We congratulate Alabama for initiating a newborn screening program for cystic fibrosis,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “More than 40 states are now screening for the disease.
More: continued here
May 15th 2008Drug InformationCystic Fibrosis
The 13th annual Breathing Life Awards will be taking place on Wednesday 28th May at Hilton Metropole and televised on Sky Real Lives (Sky channel 253) on Sunday 1st June, 9.30pm. Hosted by Carol Smillie and Dr David Bull, the glitzy awards ceremony celebrates the outstanding achievement of inspiring people that have Cystic Fibrosis (CF), the UK’s most common life-threatening inherited disease.
More: continued here
Apr 17th 2008Drug InformationCystic Fibrosis
During the Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.
More: continued here
Apr 13th 2008Drug InformationCystic Fibrosis
A team of researchers led by University of Sunderland scientists has made a major breakthrough in the fight against a deadly hospital infection which kills tens of thousands of people every year. Experts have discovered a technique for the early detection of the superbug pseudomonas aeruginosa which particularly infects patients with cystic fibrosis.
More: continued here
Apr 13th 2008Drug InformationCystic Fibrosis
During Wednesday’s Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.
More: continued here
Apr 11th 2008Drug InformationCystic Fibrosis
Illinois and Vermont have joined 37 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. In addition, the Nevada Department of Health has decided to begin regular CF screening as well. Routine screening will be implemented when state lawmakers set an implementation date.
More: continued here
Apr 11th 2008Drug InformationCystic Fibrosis
Dry airways may not only play a central role in the development of the in-herited lung disease cystic fibrosis, but also in much more common acquired chronic lung diseases such as asthma and smoker’s lung, the ciga-rette smoke-induced chronic obstructive pulmonary disease (COPD). This is the conclusion reached by scientists at Heidelberg University Hospital under the direction of Assistant Professor Dr.
More: continued here
Apr 3rd 2008Drug InformationCystic Fibrosis
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered?, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations.
More: continued here
Your best medicine news resource
